ARTICLE | Management Tracks
C-suite changes at Acelyrin could signal reprioritizations in pipeline
With CEO Shao-Lee Lin leaving, the company said it’s aiming to preserve cash resources, with a series of decision-driving clinical catalysts on the way
May 9, 2024 9:15 PM UTC
A year after conducting the largest IPO of 2023, Acelyrin has parted ways with CEO Shao-Lee Lin as it takes steps to preserve cash, including the possibility that it will cut spending on development of its lead molecule after a clinical miss last fall.
Lin’s departure was among several changes in the C-suite at Acelyrin Inc., (NASDAQ:SLRN). The company promoted its chief legal and administrative officer, Mina Kim, to CEO, and she will take a board seat...
BCIQ Company Profiles